Expression of CXCL10 is associated with response to radiotherapy and overall survival in squamous cell carcinoma of the tongue

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 4191-4198

  Rentoft, Matilda ^a   Coates, Philip John ^b   Loljung, Lotta ^a   Wilms, Torben ^c   Laurell, Göran ^a,d   Nylander, Karin ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemokines; CXCL10; Oral cancer; Prognosis; Radiotherapy; Tongue

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL4 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CXCL10 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TONGUE CARCINOMA; TREATMENT RESPONSE; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; STATISTICAL MODEL; TONGUE TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CHEMOKINE CXCL10; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TONGUE NEOPLASMS;

EID: 84902979467     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1549-6     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Sahu N, Grandis JR. New advances in molecular approaches to head and neck squamous cell carcinoma. Anticancer Drugs. 2011;22(7):656-64.
3. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev. 2007;26(3-4):645-62. (Pubitemid 350115112)
4. Grandi C, Alloisio M, Moglia D, Podrecca S, Sala L, Salvatori P, et al. Prognostic significance of lymphatic spread in head and neck carcinomas: therapeutic implications. Head Neck Surg. 1985;8(2):67-73.
5. Kalnins IK, Leonard AG, Sako K, Razack MS, Shedd DP. Correlation between prognosis and degree of lymph node involvement in carcinoma of the oral cavity. Am j surg. 1977;134(4):450-4. (Pubitemid 8201784)
6. Dinshaw KA, Agarwal JP, Ghosh-Laskar S, Gupta T, Shrivastava SK. Radical radiotherapy in head and neck squamous cell carcinoma: an analysis of prognostic and therapeutic factors. Clin Oncol (R Coll Radiol). 2006;18(5):383-9. (Pubitemid 44382294)
7. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007;26(2):241-8. (Pubitemid 47101661)
8. Shintani S, MiharaM, Li C, Nakahara Y, Hino S, Nakashiro K, et al. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci. 2003;94(10):894-900. (Pubitemid 37406972)
9. Silva P, Homer JJ, Slevin NJ, Musgrove BT, Sloan P, Price P, et al. Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clin Otolaryngol. 2007;32(5):337-45. (Pubitemid 47460304)
10. Allen CT, Judd NP, Bui JD, Uppaluri R. The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope. 2012;122(1):144-57.
11. Tong CC, Kao J, Sikora AG. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res. 2012;54(1-3):266-74.
12. Yeudall WA, Miyazaki H. Chemokines and squamous cancer of the head and neck: targets for therapeutic intervention? Expert Rev Anticancer Ther. 2007;7(3):351-60. (Pubitemid 46488339)
13. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector Tcells. J Immunol. 2008;181(5):3099-107.
14. Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, Schirlau K, et al. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Inte J Cancer. 2006;118(9):2147-57.
15. Wang J, Seethala RR, Zhang Q, GoodingW, vanWaes C, Hasegawa H, et al. Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. J Natl Cancer Inst. 2008;100(7):502-12.
16. Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Oncol Targets Ther. 2013;6:1347-61.
17. Hutchings CJ, Koglin M, Marshall FH. Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010;2(6):594-606.
18. Zhu A, Zhan W, Liang Z, Yoon Y, Yang H, Grossniklaus HE, et al. Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem. 2010;53(24):8556-68.
19. Wolff HA, Rolke D, Rave-Frank M, Schirmer M, Eicheler W, Doerfler A, et al. Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCH N) cell lines. Radiat Environ Biophys. 2011;50(1):145-54.
20. Beskow C, Agren-Cronqvist AK, Granath F, Frankendal B, Lewensohn R. Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage Ib and IIa is a strong prognostic factor for long-term survival: analysis of the Radiumhemmet data 1989-1991. Int J Gynecol Cancer. 2002;12(2):158-70. (Pubitemid 34495416)
21. Friesland S, Fernberg JO, Lundell G, Munck-Wikland E, Strander H, Lewensohn R. Prognostic impact of complete remission after preoperative irradiation of tonsillar carcinoma: a retrospective analysis of the Radiumhemmet data, 1980-1995. Int J Radiat Oncol Biol Phys. 1999;45(5):1259-66.
22. Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat. 2010;124(3):689-99.
23. Lundqvist L, Stenlund H, Laurell G, Nylander K. The importance of stromal inflammation in squamous cell carcinoma of the tongue. J Oral Pathol Med. 2012;41(5):379-83.
24. Annertz K, Anderson H, Biorklund A, Moller T, Kantola S, Mork J, et al. Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults. Int J Cancer. 2002;101(1):95-9. (Pubitemid 34833003)
25. Atula S, Grenman R, Laippala P, Syrjanen S. Cancer of the tongue in patients younger than 40 years. A distinct entity? Arch Otolaryngol Head Neck Surg. 1996;122(12):1313-9. (Pubitemid 26408912)
26. Garavello W, Spreafico R, Gaini RM. Oral tongue cancer in young patients: a matched analysis. Oral Oncol. 2007;43(9):894-7. (Pubitemid 47369252)
27. Sarkaria JN, Harari PM. Oral tongue cancer in young adults less than 40 years of age: rationale for aggressive therapy. Head Neck. 1994;16(2):107-11. (Pubitemid 24080603)
28. Schantz SP, Yu GP. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg. 2002;128(3):268-74. (Pubitemid 34218579)
29. Pytynia KB, Grant JR, Etzel CJ, Roberts D, Wei Q, Sturgis EM. Matched analysis of survival in patients with squamous cell carcinoma of the head and neck diagnosed before and after 40 years of age. Arch Otolaryngol Head Neck Surg. 2004;130(7):869-73. (Pubitemid 38915975)
30. Rentoft M, Coates PJ, Laurell G, Nylander K. Transcriptional profiling of formalin fixed paraffin embedded tissue: pitfalls and recommendations for identifying biologically relevant changes. PLoS ONE. 2012;7(4):e35276.
31. Calmon MF, Rodrigues RV, Kaneto CM, Moura RP, Silva SD, Mota LD, et al. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia (New York, NY). 2009;11(12):1329-39.
32. Rentoft M, Hultin S, Coates PJ, Laurell G, Nylander K. Tubulin alpha-6 chain is a stably expressed reference gene in archival samples of normal oral tissue and oral squamous cell carcinoma. Exp Ther Med. 2010;1(3):419-23.
33. Schantz SP, Hsu TC, Ainslie N, Moser RP. Young adults with head and neck cancer express increased susceptibility to mutagen-induced chromosome damage. JAMA. 1989;262(23):3313-5. (Pubitemid 20012554)
34. Boldrup L, Coates PJ, Laurell G, Nylander K. Differences in p63 expression in SCCHN tumours of different sub-sites within the oral cavity. Oral Oncol. 2011;47(9):861-5.
35. Ziober AF, Patel KR, Alawi F, Gimotty P, Weber RS, Feldman MM, et al. Identification of a gene signature for rapid screening of oral squamous cell carcinoma. Clin Cancer Res. 2006;12(20 Pt 1):5960-71. (Pubitemid 44703755)
36. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (review). Oncol Lett. 2011;2(4):583-9.
37. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells - significant roles of CXCL10. Cancer Res. 2009;69(4):1587-95.
38. Struyf S, Burdick MD, Peeters E, Van den Broeck K, Dillen C, Proost P, et al. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007;67(12):5940-8. (Pubitemid 46985030)
39. Lu XL, Jiang XB, Liu RE, Zhang SM. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNAvaccine and IP-10. Vaccine. 2008;26(42):5352-7.
40. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res. 2007;67(7):3396-405. (Pubitemid 46724880)
41. Pellegrino A, Antonaci F, Russo F, Merchionne F, Ribatti D, Vacca A, et al. CXCR3-binding chemokines in multiple myeloma. Cancer Lett. 2004;207(2):221-7. (Pubitemid 38457044)
42. Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene. 2007;26(32):4679-88. (Pubitemid 47067410)
43. Lo BK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol. 2010;176(5):2435-46.
44. Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, et al. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. Clin Cancer Res. 2013;19(2):336-46.
45. Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP, et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett. 2004;92(1-2):171-8. (Pubitemid 38470065)
46. Kawada K, Sonoshita M, Sakashita H, Takabayashi A, Yamaoka Y, Manabe T, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 2004;64(11):4010-7. (Pubitemid 38697317)
47. Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, et al. Antagonism of CXCR3 inhibits lungmetastasis in a murine model of metastatic breast cancer. Cancer Res. 2006;66(15):7701-7. (Pubitemid 44289229)
48. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008;267(2):226-44.
49. Wu Q, Dhir R, Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer. 2012;11(3).
50. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+CXC chemokine-induced angiogenic activity. J Immunol. 2000;165(9):5269-77.
51. WenteMN, Keane MP, BurdickMD, Friess H, BuchlerMW, Ceyhan GO, et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett. 2006;241(2):221-7. (Pubitemid 44163040)
52. Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z, et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer. 2009;125(5):1027-37.
53. Romanini J, Mielcke TR, Leal PC, Figueiredo CP, Calixto JB, Morrone FB, et al. The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma. Investig New Drugs. 2012;30(4):1371-8.